[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endoscopic-retrograde-cholangiopancreatography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endoscopic-retrograde-cholangiopancreatography":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,79,101,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100626800","teas-for-sedation-during-ercp-a-multicenter-trial-with-mechanistic-substudy-100626800",false,"NCT07440342","TEAS for Sedation During ERCP: A Multicenter Trial With Mechanistic Substudy","Transcutaneous Electrical Acupoint Stimulation Combined With Traditional Conscious Sedation for Endoscopic Retrograde Cholangiopancreatography: A Prospective, Randomized, Sham-Controlled, Multicenter Trial With Mechanistic Substudy","TEAS-ERCP-MC","1\\. Inclusion Criteria:\n\n1. Patients aged 18-85 years scheduled for elective diagnostic or therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for pancreaticobiliary indications.\n2. American Society of Anesthesiologists (ASA) physical status classification I, II, or III.\n3. Body mass index (BMI) between 18 and 30 kg\u002Fm².\n4. Willing and able to provide written informed consent.\n\n2\\. Exclusion Criteria:\n\n1. Known allergy or contraindication to meperidine, diazepam, or any other medication used in the protocol.\n2. Chronic use of benzodiazepines or opioids (regular use more than three times per week in the preceding three months).\n3. Severe cardiopulmonary, hepatic, or renal dysfunction (e.g., New York Heart Association class III or IV heart failure, uncontrolled chronic obstructive pulmonary disease, estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m², active liver disease).\n4. Anticipated difficult airway (Mallampati score IV, mouth opening \\\u003C3 cm, thyromental distance \\\u003C6 cm).\n5. Untreated or severe obstructive sleep apnea requiring continuous positive airway pressure therapy.\n6. Pregnancy or breastfeeding.\n7. Psychiatric or cognitive disorders precluding cooperation or valid assessment (e.g., severe anxiety, cognitive impairment).\n8. Pre-induction resting heart rate \\\u003C50 beats per minute or second-degree or higher atrioventricular block.\n9. Conditions predisposing to aspiration (e.g., gastric outlet obstruction, previous esophageal or gastric surgery with delayed emptying).\n10. Previous exposure to transcutaneous electrical acupoint stimulation or knowledge of TEAS that could compromise blinding for the sham procedure.\n11. Skin lesions, infections, or electronic implants at or near the proposed acupoint locations.\n12. Inability to provide informed consent.\n\n3\\. Dropout Criteria:\n\n1. Requirement for conversion to general anesthesia due to failed sedation or clinical necessity.\n2. Occurrence of a serious adverse event related to the study intervention (e.g., severe allergic reaction, hemodynamic collapse).\n3. Life-threatening deterioration during endoscopy (e.g., uncontrolled bleeding, respiratory failure, cardiac arrest).\n4. Voluntary withdrawal of consent by participant or legal representative at any time.\n5. Occurrence of a major ERCP-related complication (e.g., perforation, major bleeding, severe pancreatitis) requiring surgical or intensive care intervention.\n6. Principal investigator-identified safety risks (e.g., sepsis, acute liver failure).","ALL","18 Years","85 Years",{"count":21,"type":22},130,"ESTIMATED","INTERVENTIONAL",[25],"NA","1. The goal of this clinical trial is to learn if transcutaneous electrical acupoint stimulation (TEAS), a non-invasive therapy that applies mild electrical current to specific points on the skin, can help patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) better tolerate the procedure and experience fewer complications related to sedation. It will also explore the underlying neuro-endocrine-immune mechanisms by measuring changes in serum biomarkers.\n2. The main questions the study aims to answer are:\n\n(1)Does TEAS reduce the incidence of sedation-related adverse events (such as low blood oxygen, low blood pressure, or breathing problems) during ERCP? (2)Does TEAS improve patient comfort and reduce the need for additional sedative medications during the procedure? (3)Does TEAS lead to faster recovery and higher patient and physician satisfaction? (4) Does TEAS modulate the neuro-endocrine-immune network, as reflected by changes in serum β-endorphin, cortisol, TNF-α, and IL-6 levels?\n\n3.Researchers will compare two approaches:\n\n1. Active TEAS: Electrical stimulation at specific points on the legs and arms before and during ERCP.\n2. Sham TEAS: Pads placed on the same points but no electrical stimulation delivered (the device appears active).\n\n4.All participants will receive standard conscious sedation with meperidine and diazepam, which is commonly used for ERCP in many centers. Participants will be randomly assigned to one of the two groups. The study will measure sedation-related complications, pain levels, medication requirements, recovery times, satisfaction scores, and changes in serum biomarkers (β-endorphin, cortisol, TNF-α, IL-6).",[28,29,30,31],"Endoscopic Retrograde Cholangiopancreatography","Conscious Sedation Adverse Event","Procedural Pain","Sedation-related Complications",[33,34,35,36,37,38,39,40,41,42,43],"Transcutaneous Electrical Acupoint Stimulation","ERCP","Conscious Sedation","Diazepam","Sedation-Related Adverse Events","Acupuncture","Non-Pharmacological Intervention","Neuro-endocrine-immune Mechanisms","Inflammatory Cytokines","Cortisol","β-endorphin","NOT_YET_RECRUITING","2026-06-14",{"date":47,"type":48},"2026-06-16","ACTUAL",{"date":50,"type":22},"2026-09-01",{"date":52,"type":22},"2027-10-01",{"name":54,"class":55},"Beijing 302 Hospital","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100637228","hfnc-versus-microstream-advance-nasal-cannula-for-oxygenation-during-ercp-100637228","NCT07611903","HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP","Inclusion Criteria:\n\n* Patients aged 18 to 84 years\n* ASA physical status I-III\n* Patients scheduled to undergo ERCP\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Recent history of upper respiratory tract infection\n* History of lung cancer\n* Chronic obstructive pulmonary disease\n* Asthma\n* Body mass index greater than 35 kg\u002Fm²\n* Refusal to participate in the study","84 Years",{"count":65,"type":22},74,[25],"Endoscopic retrograde cholangiopancreatography (ERCP) procedures are commonly performed under deep sedation and are associated with a risk of hypoxemia, particularly in prone or semi-prone positions. High-flow nasal cannula (HFNC) therapy may improve oxygenation by delivering heated and humidified oxygen at high flow rates, while the Microstream Advance nasal cannula provides simultaneous nasal oxygen delivery and oral oxygen insufflation.\n\nThis prospective randomized study aims to compare the effectiveness of HFNC and Microstream Advance nasal cannula in maintaining oxygenation during ERCP procedures. Patients undergoing ERCP will be randomized into two groups receiving either HFNC or Microstream Advance nasal cannula oxygen support during sedation.\n\nThe primary outcomes are the incidence of desaturation and oxygen reserve index (ORi) measurements during the procedure. Secondary outcomes include time to achieve target ORi levels, respiratory complications, and procedure-related adverse events.",[28,69],"Hypoxemia","2026-05-28",{"date":72,"type":48},"2026-06-01",{"date":74,"type":22},"2026-06-29",{"date":76,"type":22},"2026-12-30",{"name":78,"class":55},"Kocaeli University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":56},"100393856","does-pancreatic-stent-decrease-the-risk-of-pancreatitis-after-pancreatic-sphincterotomy-for-difficult-cannulation-100393856","NCT04408482","Does Pancreatic Stent Decrease the Risk of Pancreatitis After Pancreatic Sphincterotomy for Difficult Cannulation?","Inclusion Criteria:\n\n* Consecutive patients with naïve papilla presenting to ERCP with indication of common bile duct (CBD) cannulation will be considered to the study.\n\nExclusion Criteria:\n\n* Exclusion criteria are age below 18 years, acute pancreatitis and no consent to the study.","100 Years",{"count":87,"type":22},268,[25],"The purpose of the study is to compare the risk of PEP after pancreatic sphincterotomy performed for difficult cannulation in a group of patients with and in a group of patients without placement of a prophylactic pancreatic stent. The definition of difficult cannulation is defined according to the literature.",[28],"RECRUITING","2026-02-27",{"date":94,"type":48},"2026-03-03",{"date":96,"type":48},"2020-08-01",{"date":98,"type":22},"2028-09-01",{"name":100,"class":55},"Helsinki University Central Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":56},"100575791","observational-study-to-develop-a-predictive-score-for-adverse-events-post-ercp-100575791","NCT06776874","Observational Study to Develop a Predictive Score for Adverse Events Post ERCP","Studio Osservazionale Per lo Sviluppo di Uno Score Predittivo Degli Eventi Avversi Post-colangiopancreatografia Retrograda Endoscopica (ERCP)","Inclusion Criteria:\n\n* Age \\>18 years\n* Patients admitted with hepato-biliary-pancreatic disease or other pathological conditions that require treatment by ERCP\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* None",{"count":109,"type":22},981,"OBSERVATIONAL","The main objective of the study is: the identification of independent factors associated with an increased risk of post-ERCP complications. Other objectives are: the development of a predictive model of events post-ERCP adverse events and its validation; geographic validation of a predictive model already published in the literature using data collected during the study and the evaluation of the rate of post-ERCP AEs in the centers involved in the study.",[28],"2025-01-14",{"date":115,"type":48},"2025-01-15",{"date":117,"type":48},"2021-03-24",{"date":119,"type":22},"2025-12-31",{"name":121,"class":55},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":56},"100571153","biodegradable-stents-in-liver-transplant-recipients-for-treatment-of-biliary-anastomotic-strictures-100571153","NCT06716541","Biodegradable Stents in Liver Transplant RecipIents for Treatment of Biliary Anastomotic Strictures","Biodegradable Stents Versus Plastic Stents for Treatment of Biliary Anastomotic Strictures in Liver Transplant RecipIents","BRILLIANT","Inclusion Criteria:\n\n* Age ≥18 years\n* Liver transplant recipients\n* Duct-to-duct biliary anastomosis\n* Anastomotic biliary stricture (cholestasis unexplained by other causes and\u002For liver biopsy showing altered biliary drainage and\u002For anastomotic stricture on MRCP)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Hepaticojejunoanastomosis\n* Physical and\u002For psychological inability to understand the aims of the research and to adequately cooperate\n* Pregnancy",{"count":131,"type":22},70,[25],"Biliary complications after liver transplantation (LT) remain common and are associated with higher morbidity in liver transplant recipients and liver graft failure. Anastomotic biliary strictures are the most common biliary strictures after LT. Today, the gold standard for treatment remains endoscopic retrograde cholangiopancreatography (ERCP) with either multiple plastic stenting (MPS) or fully covered metal stents. These methods have disadvantages such as the need for repeated ERCP procedures, high costs or the risk of migration.\n\nBiodegradable stents (BDS) are a novel type of stents made from various synthetic polymers or their copolymers, which are now being used in a variety of medical fields, including the pancreatobiliary tract.The use of biodegradable stents has shown good potential in the treatment of benign biliary strictures. However, overall data on their endoscopic use in liver transplant recipients, particularly in the treatment of anastomotic biliary strictures, are scarce. Most studies have either been in animal models, using percutaneously implanted stents, or in non-transplanted patients. There are no randomised controlled trials investigating their use in LT patients. Based on the available evidence, the use of BDS in the treatment of anastomotic biliary strictures in liver transplant recipients appears to be a promising technique that may be as effective as the standard treatment with MPS, but may reduce the number of ERCP procedures and eliminate the risk of migration.\n\nThe aim of this randomised prospective study is to compare the difference in rates of anastomotic stricture resolution between the active (BDS) and control (MPS) groups to demonstrate non-inferiority of the biodegradable stents. Outcomes will be classified as complete resolution (no significant stricture at the anastomotic site on imaging and resolution of cholestasis), significant response (relative stricture and resolution of cholestasis) or failure (persistent stricture and\u002For persistent cholestasis). Secondary outcomes are technical feasibility, immediate and late complications.",[135,136,28],"Liver Transplant, Complications","Biliary Anastomotic Stenosis","2024-12-03",{"date":139,"type":48},"2024-12-04",{"date":141,"type":48},"2024-11-01",{"date":143,"type":22},"2027-12-31",{"name":145,"class":146},"Institute for Clinical and Experimental Medicine","OTHER_GOV"]